Ranibizumab combined with low-dose sorafenib for exudative age-related macular degeneration

Teresa Diago1, Jose S Pulido, Julian R Molina

  • 1Department of Ophthalmology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.

Mayo Clinic Proceedings
|February 5, 2008
PubMed

Insights

Adding sorafenib to ranibizumab therapy showed potential benefits for patients with wet age-related macular degeneration (AMD). Optical coherence tomography revealed marked improvement in both cases, suggesting further investigation in randomized trials.

Area of Science:

  • Ophthalmology
  • Oncology
  • Pharmacology

Background:

  • Angiogenesis is implicated in both cancer and exudative age-related macular degeneration (AMD).
  • Angiogenesis inhibition is a therapeutic strategy for these conditions.
  • Standard treatment for neovascular AMD often involves anti-vascular endothelial growth factor (VEGF) agents.

Observation:

  • Two cases of recurrent exudative AMD were treated with oral sorafenib (a tyrosine kinase inhibitor) added to intravitreal ranibizumab (an anti-VEGF antibody).
  • Patients were monitored using visual acuity, fluorescein angiography, fundoscopy, and optical coherence tomography (OCT).

Findings:

  • One patient experienced improved visual acuity from 20/70 to 20/60 with sorafenib therapy.
  • Both patients showed marked improvement on OCT.
  • Both patients appeared to benefit from low-dose oral sorafenib monotherapy after initial combination treatment.

Implications:

  • Adding sorafenib to standard therapy may benefit patients with neovascular AMD.
  • Further investigation through randomized clinical trials is warranted.
  • Sorafenib's potential role in managing exudative AMD warrants exploration.

Related Concept Videos

Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...